Our study showed that simvastatin is a promising treatment for HMGCS2‐induced resistance and may affect tolerance delay when used in combination with NTRK‐TKI at clinical concentrations in an NTRK‐rearranged tumor. The gene discussed is HMGCS2; the disease is neoplasm.